Skip to main content
An official website of the United States government

idelalisib

View Patient Information
An orally bioavailable, small molecule inhibitor of the delta isoform of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities. Idelalisib inhibits the production of the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3), preventing the activation of the PI3K signaling pathway and inhibiting tumor cell proliferation, motility, and survival. Unlike other isoforms of PI3K, PI3K-delta is expressed primarily in hematopoietic lineages. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:phosphoinositide-3 kinase delta inhibitor CAL-101
PI3K delta inhibitor CAL-101
US brand name:Zydelig
Code name:CAL-101
GS-1101
Chemical structure:5-fluoro-3-phenyl-2-([S)]-1-[9H-purin-6-ylamino]-propyl)-3H-quinazolin-4-one
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search